STOCK TITAN

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Karyopharm Therapeutics (Nasdaq: KPTI) has granted 10,500 restricted stock units (RSUs) to three newly-hired employees as of October 31, 2024. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and will vest over three years, with 33 1/3% vesting annually. The grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of employment termination following a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI) ha concesso 10.500 unità di azioni riservate (RSU) a tre nuovi dipendenti a partire dal 31 ottobre 2024. Le RSU sono state assegnate nell'ambito del Piano di Incentivo Azionario di Induzione 2022 dell'azienda e si matureranno in tre anni, con il 33 1/3% che matura annualmente. Le concessioni fungono da incentivo all'occupazione in conformità con la Regola di Quotazione 5635(c)(4) di Nasdaq. Le RSU includono disposizioni per la maturazione accelerata in caso di cessazione del rapporto di lavoro a seguito di un evento di cambiamento di controllo.

Karyopharm Therapeutics (Nasdaq: KPTI) ha otorgado 10,500 unidades de acciones restringidas (RSUs) a tres empleados recién contratados a partir del 31 de octubre de 2024. Las RSUs se concedieron bajo el Plan de Incentivos de Acciones de Inducción 2022 de la compañía y se acumularán durante tres años, con un 33 1/3% que se acumula anualmente. Las concesiones sirven como incentivos laborales en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq. Las RSUs incluyen disposiciones de acumulación acelerada en caso de terminación del empleo tras un evento de cambio de control.

Karyopharm Therapeutics (Nasdaq: KPTI)는 2024년 10월 31일자로 세 명의 신규 직원에게 10,500개의 제한된 주식 단위(RSU)를 부여했습니다. 이 RSU는 회사의 2022년도 유도 주식 인센티브 계획에 따라 수여되었으며, 3년 동안 매년 33 1/3%씩 분할 지급됩니다. 이 보상은 Nasdaq 상장 규정 5635(c)(4) 준수 차원에서 고용 유도 역할을 합니다. RSU에는 경영권 변화 이후 고용 종료 시 가속화된 지급 조항이 포함되어 있습니다.

Karyopharm Therapeutics (Nasdaq: KPTI) a accordé 10 500 unités d'actions restreintes (RSU) à trois employés nouvellement embauchés à compter du 31 octobre 2024. Les RSU ont été attribuées dans le cadre du Plan d'incitation à l'action de 2022 de l'entreprise et seront acquises sur une période de trois ans, avec 33 1/3 % acquérant chaque année. Les attributions servent d'incitation à l'emploi conformément à la règle d'inscription 5635(c)(4) de Nasdaq. Les RSU incluent des dispositions d'acquisition accélérée en cas de licenciement suite à un changement de contrôle.

Karyopharm Therapeutics (Nasdaq: KPTI) hat zum 31. Oktober 2024 10.500 beschränkte Aktieneinheiten (RSUs) an drei neu eingestellte Mitarbeiter vergeben. Die RSUs wurden im Rahmen des Aktienanreizplans 2022 des Unternehmens vergeben und werden über drei Jahre verteilt, wobei jährlich 33 1/3% anfallen. Die Zusagen dienen als Beschäftigungsanreize gemäß der Nasdaq-Listungsregel 5635(c)(4). Die RSUs beinhaltenBestimmungen zur beschleunigten Vesting im Falle einer Beendigung des Arbeitsverhältnisses nach einem Kontrollwechsel.

Positive
  • None.
Negative
  • None.

NEWTON, Mass., Nov. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,500 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of October 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­ U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302290086.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

How many RSUs did Karyopharm Therapeutics (KPTI) grant on October 31, 2024?

Karyopharm Therapeutics granted 10,500 restricted stock units (RSUs) to three newly-hired employees.

What is the vesting schedule for KPTI's October 2024 RSU grants?

The RSUs will vest over three years, with 33 1/3% of the shares vesting on each of the three consecutive anniversaries of the Grant Date.

Under what plan were KPTI's October 2024 RSUs granted?

The RSUs were granted under Karyopharm's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

KPTI Rankings

KPTI Latest News

KPTI Stock Data

104.70M
117.63M
6.04%
50.01%
14.12%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON